Efficacy and Safety of Jinshuibao Capsule on Diabetic Kidney Disease

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. Identifier: NCT03164785
Recruitment Status : Recruiting
First Posted : May 24, 2017
Last Update Posted : September 7, 2018
Information provided by (Responsible Party):
Zhiguang Zhou, Second Xiangya Hospital of Central South University

Brief Summary:
The purpose of this study is to investigate the therapeutic effect and safety of Jinshuibao Capsule on diabetic kidney disease in T2DM patients.

Condition or disease Intervention/treatment Phase
Type 2 Diabetes Mellitus Diabetic Kidney Disease Drug: Jinshuibao Capsule Phase 2 Phase 3

Detailed Description:
Diabetic Kidney Disease (DKD) is one of the most important microvascular complications of diabetes and is the leading cause of end-stage renal disease. Intensive glycemic and blood pressure control, combined with renin - angiotensin system blocking therapy (including ACEI and ARB drugs), has to a certain extent, delayed the progression of DKD, but still cannot completely block its development. Cordyceps sinensis is a traditional Chinese medicine and Jinshuibao Capsule is its artificial preparation, with the effect of renoprotection. However, its clinical application in diabetic kidney disease is not well-defined so far. The aim of this study is to investigate the potential use of Jinshuibao Capsule on microalbuminuria in T2DM.

Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 200 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Efficacy and Safety of Jinshuibao Capsule as Add-on Therapy to Angiotensin II Receptor Blockers on Diabetic Kidney Disease in Patients With Type 2 Diabetes Mellitus
Actual Study Start Date : November 17, 2017
Estimated Primary Completion Date : December 2018
Estimated Study Completion Date : April 2019

Resource links provided by the National Library of Medicine

Arm Intervention/treatment
Experimental: Treatment Group

Treatment:subjects receive Jinshuibao Capsule. ARB will be continued as a routine therapy.

Counseling: subjects will follow through regular check-up and receive lifestyle and other diabetes treatment counseling

Drug: Jinshuibao Capsule
1.98g t.i.d. p.o. for 6 months
Other Names:
  • Jinshuibao Jiaonang
  • Cordyceps sinensis
  • Artificial Cordyceps sinensis powder

No Intervention: Control Group
Patients receive a standard dose of ARB drug as a routine therapy. Counseling: subjects will follow through regular check-up and receive lifestyle and other diabetes treatment counseling

Primary Outcome Measures :
  1. Change in urine albumin creatine ratio (ACR). [ Time Frame: Baseline and 1,2,3,6 months. ]
    First morning urine (10-15ml) of the subject is collected with a clean urine collection tube (or vial).

Secondary Outcome Measures :
  1. The incidence of ≧30% decline in eGFR from baseline. [ Time Frame: half a year ]
    Monitoring changes in glomerular functions measured in estimated glomerular filtration rate (eGFR) [CKD-EPI creatinine-cystatin equation (2012)].

  2. Change in urine α1-microglobulin. [ Time Frame: Baseline and 1,2,3,6 months. ]
  3. Change in urine β2-microglobulin. [ Time Frame: Baseline and 1,2,3,6 months. ]
  4. Change in urine N-acetyl-β-D-glucosidase. [ Time Frame: Baseline and 1,2,3,6 months. ]
  5. Change in urine neutrophil gelatinase-associated lipocalin. [ Time Frame: Baseline and 1,2,3,6 months. ]
  6. Change in inflammation level. [ Time Frame: Baseline and 1,2,3,6 months. ]
    Change in hs-CRP level.

  7. Change in HbA1c. [ Time Frame: Baseline and 1,3,6 months. ]
  8. Change in blood pressure control. [ Time Frame: Baseline and 1,2,3,6 months. ]
  9. Change in blood lipids. [ Time Frame: Baseline and 1,3,6 months. ]
  10. Life quality evaluation [ Time Frame: Baseline and 6 months. ]
    Change in SF-36 Scale score.

  11. Incidence of Treatment-Emergent Adverse Events [ Time Frame: half a year ]
    Treatment-related adverse events as assessed by deterioration of liver functions with other reasons excluded, self-report of gastrointestinal symptoms associated with drug intake, etc.

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Ages Eligible for Study:   30 Years to 75 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  1. Subjects with written informed consent.
  2. Type 2 diabetes according to 1999 WHO criteria.
  3. Age: 30-75 years.
  4. HbA1c < 11%.
  5. Stage III diabetic kidney disease:

    5.1 microalbuminuria: 30 mg / g < urinary albumin creatinine ratio (ACR) < 300 mg / g, positive for at least two in three times.

    5.2 renal function: eGFR ≧ 30 ml / min / 1.73 ㎡.

  6. Stable use of a standard dose of angiotensin II receptor blocker ≧ 3 months.
  7. Childbearing-age women with contraceptive measures.

Exclusion Criteria:

  1. Type 1 Diabetes Mellitus.
  2. Non-diabetic urinary system diseases (Urinary tract obstruction, bladder emptying disorders, severe benign prostatic hyperplasia, renal vascular disease, post-renal transplantation, active urinary tract infection,etc.)
  3. Other serious diseases [severe hypertension ((defined as SBP > 200 mmHg and/or DBP > 110 mmHg, or requiring ≧3 anti-hypertensive drugs simultaneously), cardiovascular and cerebrovascular events within 6 months, autoimmune diseases implicating the urinary system, chronic or acute pancreatitis, malignancy, hepatic abnormalities (transaminase ≧ 3.0 x UNL), severe gastrointestinal diseases, other endocrine diseases affecting the urinary system, etc.]
  4. Allergic to Cordyceps sinensis, use of ACEIs, any use of Cordyceps sinensis preparations, systemic glucocorticoid treatment ≧ 7 days within a month, use of nephrotoxic drugs within 3 months, alcohol or psychotropic drug dependence, etc.
  5. Presence of acute metabolic disorders (DKA,HHS); history of surgery, severe trauma and other stress conditions.
  6. Female patients who are pregnant or breastfeeding. Any medical condition that, in the opinion of the investigator, will interfere with participation in the trial.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT03164785

Contact: Zhiguang Zhou, MD/PhD 86-731-85292154

China, Hunan
The Second Xiangya Hospital of Central South University Recruiting
Changsha, Hunan, China, 410011
Contact: Zhou Zhiguang, PhD    +8613873104348   
Contact: Cao Chuqing, MD    +8615073136917   
Principal Investigator: Zhou Zhiguang, PhD         
Sub-Investigator: Cao Chuqing, MD         
Sub-Investigator: Yang Shuting, BA         
Sponsors and Collaborators
Second Xiangya Hospital of Central South University
Principal Investigator: Zhiguang Zhou, MD/PhD Second Xiangya Hospital, Central South University

Responsible Party: Zhiguang Zhou, Head of Endocrinology Department, Second Xiangya Hospital of Central South University Identifier: NCT03164785     History of Changes
Other Study ID Numbers: JSB201601
First Posted: May 24, 2017    Key Record Dates
Last Update Posted: September 7, 2018
Last Verified: August 2018
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No
Plan Description: The results belongs to the principal investigator and collaborators.

Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Product Manufactured in and Exported from the U.S.: No

Additional relevant MeSH terms:
Diabetic Nephropathies
Diabetes Mellitus
Diabetes Mellitus, Type 2
Kidney Diseases
Glucose Metabolism Disorders
Metabolic Diseases
Endocrine System Diseases
Urologic Diseases
Diabetes Complications
Angiotensin Receptor Antagonists
Molecular Mechanisms of Pharmacological Action